Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Neurosense Therapeutics Ltd. ( (NRSN) ).
As of August 20, 2025, NeuroSense Therapeutics Ltd. reported that approximately 20% of participants from their Phase 2a study on ALS, including those under compassionate use, have been on PrimeC for over 5.5 years, with no new safety concerns observed. This long-term tolerance and safety of PrimeC may enhance the company’s positioning in the neurodegenerative treatment market, potentially impacting stakeholders positively by demonstrating the drug’s sustained efficacy and safety.
The most recent analyst rating on (NRSN) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock, see the NRSN Stock Forecast page.
Spark’s Take on NRSN Stock
According to Spark, TipRanks’ AI Analyst, NRSN is a Underperform.
Neurosense Therapeutics Ltd. faces substantial financial difficulties, including no revenue and negative equity, severely impacting its overall score. Technical indicators are neutral but do not offset financial weaknesses. The valuation is unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on NRSN stock, click here.
More about Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. operates in the biotechnology industry, focusing on the development of treatments for neurodegenerative diseases. The company is primarily known for its product PrimeC, which is aimed at treating Amyotrophic Lateral Sclerosis (ALS).
Average Trading Volume: 364,425
Technical Sentiment Signal: Sell
Current Market Cap: $30.75M
Find detailed analytics on NRSN stock on TipRanks’ Stock Analysis page.